Our funding

The NC3Rs has an annual budget of around £10 million. We receive core funding from the Medical Research Council (MRC), the Biotechnology and Biological Sciences Research Council (BBSRC) and the Home Office.

We also receive funding for specific programmes from the charitable and commercial sectors, and co-funding from other research funders. In 2014/15 this includes the following organisations:

Association of the British Pharmaceutical Industry1 
Alzheimer's Research UK
Department for Environment, Food and Rural Affairs
Engineering and Physical Sciences Research Council
GlaxoSmithKline
MedImmune
SCJohnson
Shell
Syngenta
Technology Strategy Board
The Dow Chemical Company
Unilever
Wellcome Trust

 

in accordance with the ABPI's Code of Practice regulating the pharmaceutical industry, the following companies have provided funding to the NC3Rs as part of the ABPI-NC3Rs collaboration: AstraZeneca, Covance, Eli Lily & Co., GlaxoSmithKline, Huntingdon Life Sciences,  Novartis, Pfizer, Shire, Takeda and UCB.